KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
-7.91%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$260M
AUM Growth
+$260M
(-15%)
Cap. Flow
-$26.1M
Cap. Flow
% of AUM
-10.02%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
5
Reduced
4
Closed
1
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$25M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$1.16M |
| 3 |
Biogen
BIIB
|
$35.9K |
| 4 |
Gilead Sciences
GILD
|
$30.3K |
| 5 |
Elanco Animal Health
ELAN
|
$20.4K |
Top Sells
| 1 |
Amgen
AMGN
|
$39.7M |
| 2 |
McKesson
MCK
|
$10.9M |
| 3 |
United Therapeutics
UTHR
|
$814K |
| 4 |
IVC
Invacare Corporation
IVC
|
$800K |
| 5 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
$78.1K |
Sector Composition
| 1 | Healthcare | 96.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$13.8B
| $43.1M | 16.54% | 540,094 -10,205 | -2% | -$814K |
|
|
2
Biogen
BIIB
$19.4B
| $41.1M | 15.8% | 176,710 +154 | +0.1% | +$35.9K |
|
|
3
McKesson
MCK
$85.4B
| $40.1M | 15.39% | 293,297 -80,000 | -21% | -$10.9M |
|
|
4
Gilead Sciences
GILD
$140B
| $35M | 13.43% | 551,715 +478 | +0.1% | +$30.3K |
|
|
5
Enanta Pharmaceuticals
ENTA
$180M
| $30M | 11.51% | 498,874 +19,298 | +4% | +$1.16M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $25M | 9.59% | +255,000 | New | +$25M |
|
|
7
Elanco Animal Health
ELAN
$9.12B
| $23.7M | 9.11% | 892,620 +769 | +0.1% | +$20.4K |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $11.1M | 4.26% | 3,890,324 -27,420 | -0.7% | -$78.1K |
|
|
IVC
9
DELISTED
Invacare Corporation
IVC
| $9.19M | 3.53% | 1,224,761 -106,648 | -8% | -$800K |
|
10
Avanos Medical
AVNS
$554M
| $2.23M | 0.85% | 59,429 +51 | +0.1% | +$1.91K |
|
|
11
Amgen
AMGN
$155B
| – | – | -215,402 | Closed | -$39.7M |
|